The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.

PURPOSE EGR-1 is an immediate early gene with diverse functions that include the suppression of growth. EGR-1 is down-regulated many cancer cell types, suggesting a tumor suppressor role, and may critically involve the p53 pathway. The aim of this work was to measure the expression of EGR-1 and the p16/INK4a/ARF-Mdm2-p53 pathway status in fresh human gliomas. EXPERIMENTAL DESIGN Thirty-one human gliomas with different grades of malignancy were investigated for Egr-1 mRNA and the protein expression, frequency, and spectrum of p53 gene mutations, mdm2 gene amplification, and p16/INK4a/ARF allele loss. RESULTS The amplification of Mdm2 and the deletion of the p16/INK4a gene was found in 3 and 5 cases, respectively, whereas mutations of p53, including two novel mutations, were observed in 10 other cases. The three types of changes occurred strictly mutually exclusively, emphasizing that these genes operate in a common pathway critical to glioma progression. EGR-1 mRNA was significantly down-regulated in astrocytomas (14.7 +/- 5.1%) and in glioblastomas (33.6 +/- 10.0%) versus normal brain. Overall, EGR-1 mRNA was strongly suppressed (average, 15.2 +/- 13.9%) in 27 of 31 cases (87%), independent of changes in p16/INK4a/ARF and Mdm2; whereas 4 of 31 cases with residual EGR-1 expression as well as the highest EGR-1 variance segregated with p53 mutations. Immunohistochemical analyses confirmed the suppression of EGR-1 protein. CONCLUSIONS These results indicate that EGR-1 is commonly suppressed in gliomas independent of p16/INK4a/ARF and Mdm2 and that suppression is less crucial in tumors bearing p53 mutations, and these results implicate an EGR-1 growth regulatory mechanism as a target of inactivation during tumor progression.

[1]  J. Milbrandt,et al.  Ionizing Radiation Down-regulates p53 Protein in Primary Egr-1−/− Mouse Embryonic Fibroblast Cells Causing Enhanced Resistance to Apoptosis* , 2001, The Journal of Biological Chemistry.

[2]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.

[3]  C. Sherr.  The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[4]  D. Mercola,et al.  The Transcription Factor EGR-1 Directly Transactivates the Fibronectin Gene and Enhances Attachment of Human Glioblastoma Cell Line U251* , 2000, The Journal of Biological Chemistry.

[5]  A. López-Guillermo,et al.  INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. , 2000, The American journal of pathology.

[6]  M. Roussel,et al.  Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.

[7]  N. Tsuchida,et al.  The p16INK4alpha/p19ARF gene mutations are infrequent and are mutually exclusive to p53 mutations in Indian oral squamous cell carcinomas. , 2000, International Journal of Oncology.

[8]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[9]  D. Miller,et al.  Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. , 2000, Human pathology.

[10]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[11]  A. Merlo,et al.  Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.

[12]  Ruo-Pan Huang,et al.  p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis , 1999, Oncogene.

[13]  Ruo-Pan Huang,et al.  The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-β1, Fibronectin, and Plasminogen Activator Inhibitor-1* , 1999, The Journal of Biological Chemistry.

[14]  M. During,et al.  Towards gene therapy for the central nervous system. , 1998, Molecular medicine today.

[15]  S. Rempel.  Molecular biology of central nervous system tumors. , 1998, Current opinion in oncology.

[16]  V. Rangnekar,et al.  Suppression of growth and transformation and induction of apoptosis by EGR-1. , 1998, Cancer gene therapy.

[17]  V. Rangnekar,et al.  Ionizing Radiation-inducible Apoptosis in the Absence of p53 Linked to Transcription Factor EGR-1* , 1997, The Journal of Biological Chemistry.

[18]  A. Beckmann,et al.  Egr transcription factors in the nervous system , 1997, Neurochemistry International.

[19]  A. Porcellini,et al.  Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells , 1997, Oncogene.

[20]  V. Rangnekar,et al.  Early Growth Response-1-dependent Apoptosis Is Mediated by p53* , 1997, The Journal of Biological Chemistry.

[21]  D. Mercola,et al.  Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation , 1997, International journal of cancer.

[22]  D. Mercola,et al.  Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. , 1996, Oncogene.

[23]  D. Mercola,et al.  Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Adamson,et al.  UV activates growth factor receptors via reactive oxygen intermediates , 1996, The Journal of cell biology.

[25]  S. Ménard,et al.  A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, Cancer research.

[26]  E. Ricevuto,et al.  Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. , 1996, The American journal of pathology.

[27]  Xiao-Fan Wang,et al.  Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.

[28]  D. Mercola,et al.  Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. , 1995, Cancer research.

[29]  V. Rangnekar,et al.  Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6 , 1995, Molecular and cellular biology.

[30]  R. Figlin,et al.  Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.

[31]  Xiao-Fan Wang,et al.  Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[33]  D. Mercola,et al.  Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. , 1994, Oncogene.

[34]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[35]  F. Rauscher,et al.  The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  R. Espinosa,et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[38]  M. Simmons,et al.  Induction of Nitric Oxide Synthase in Glial Cells , 1992, Journal of neurochemistry.

[39]  Eileen D. Adamson,et al.  A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization , 1988, Cell.

[40]  J. Milbrandt,et al.  A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. , 1987, Science.

[41]  C. Dani,et al.  Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. , 1985, Nucleic acids research.